search
Back to results

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE)

Primary Purpose

Newly Diagnosed Glioblastoma

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Marizomib
Temozolomide
radiotherapy
Sponsored by
European Organisation for Research and Treatment of Cancer - EORTC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Newly Diagnosed Glioblastoma focused on measuring Marizomib, Temozolomide, Glioblastoma, Phase III

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically confirmed newly diagnosed glioblastoma (WHO grade IV)
  • Tumor resection (gross total or partial), or biopsy only
  • Availability of FFPE tumor block or 24 unstained slides for MGMT analysis
  • Patient must be eligible for standard TMZ/RT + TMZ
  • Karnofsky performance score (KPS) ≥ 70
  • Recovered from effects of surgery, postoperative infection and other complications of surgery (if any)
  • The patient is at least 18 years of age on day of signing informed consent
  • Stable or decreasing dose of steroids for at least 1 week prior to inclusion
  • The patient has a life expectancy of at least 3 months
  • Patient has undergone a brain MRI within 14 days of randomization but after intervention (resection or biopsy)

  • The patient shows adequate organ functions as assessed by the specified laboratory values within 2 weeks prior to randomization defined as adequate bone marrow, renal and hepatic function within the following ranges:

    • WBC ≥ 3×10*9/L
    • ANC ≥ 1.5×10*9/L
    • Platelet count of ≥ 100×10*9/L independent of transfusion
    • Hemoglobin ≥ 10 g/dl
    • Total Bilirubin ≤ 1.5 ULN
    • ALT, AST, alkaline phosphatase (ALP) ≤ 2.5 × ULN
    • Serum creatinine < 1.5 x ULN or creatinine clearance (CrCl) > 30 mL/min(using the Cockcroft-Gault formula)
  • Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study treatment.
  • Patients of childbearing / reproductive potential must agree to use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1 percent per year) when used consistently and correctly. Patients must also agree not to donate sperm during the study and for 6 months after receiving the last dose of study treatment.
  • Women who are breast feeding must agree to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
  • Ability to take oral medication
  • Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Sites / Locations

  • Mayo Clinic Scottsdale
  • University of California at Irvine
  • University of California
  • John Wayne Cancer Institute
  • University of Florida
  • Mayo Clinic
  • Mayo Clinic
  • Ohio State University Comprehensive Cancer Center
  • Penn State College of Medicine, Hershey Medical Center-Penn State Neuroscience Institute
  • Innsbruck Universitaetsklinik
  • Kepler University Hospital
  • Medical University Vienna - General Hospital AKH
  • Onze Lieve Vrouw Ziekenhuis
  • GasthuisZusters Antwerpen - Sint-Augustinus
  • Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
  • Cliniques Universitaires Saint-Luc
  • Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame
  • Universitair Ziekenhuis Gent
  • C.H.U. Sart-Tilman
  • Saint John Regional Hospital
  • London Regional Cancer Center
  • Ottawa Health Research Institute
  • Windsor Regional Cancer Centre
  • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
  • BCCA - Abbotsford Centre
  • Tom Baker Cancer Centre
  • QEII Health Sciences Centre-Capital District Health Authority
  • Hamilton Health Sciences, Juravinski Cancer Centre
  • Kingston Health Sciences Centre
  • Montreal Neurological Institute and Hospital McGill University
  • CHUM - Centre Hospitalier de l'Université de Montreal - Hopital Notre-Dame
  • Hopital Du Sacre-Coeur De Montreal
  • CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
  • Allan Blair Cancer Centre
  • Sault Area Hospital
  • Regional Cancer Program of Hopital Reg. de Sudbury Reg. Hospital
  • Odette Cancer Centre - Sunnybrook Health Sciences Centre
  • University Health Network - Oci / Princess Margaret Hospital
  • Centre hospitalier regional de Trois-Rivieres
  • BC Cancer Agency
  • Bcca - Vancouver Island Cancer Centre
  • Cancercare Manitoba
  • Aarhus University Hospitals - Aarhus University Hospital (440)
  • University Hospitals Copenhagen - Rigshospitalet
  • Centre Hospitalier Departemental Vendée
  • CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer
  • CHRU de Lille
  • Institut de Cancerologie de l'Ouest
  • Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
  • Gustave Roussy
  • Universitaetsklinikum Bonn
  • Universitaetsklinik Erlangen-Neurologische Klinik (3031)
  • Klinikum Der J.W. Goethe Universitaet-Klinik und Poliklinik fur Neurochirurgie
  • UniversitaetsKlinikum Heidelberg - Head Hospital
  • Universitaetsklinikum Leipzig-Klinik für Strahlentherapie und Radioonkologie
  • Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center
  • UniversitaetsMedizin Mannheim
  • Technische Universitaet Muenchen - Klinikum Rechts Der Isar
  • Universitaetskliniken Regensburg
  • Universitaetsklinikum Tuebingen- Crona Kliniken
  • Catharina Ziekenhuis
  • Spaarne Gasthuis - Vrije Universiteit Medisch Centrum
  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
  • Medisch Centrum Haaglanden - Westeinde
  • University Medical Center Groningen
  • Academisch Ziekenhuis Maastricht
  • Radboud University Medical Center Nijmegen
  • Erasmus MC
  • Universitair Medisch Centrum - Academisch Ziekenhuis
  • Oslo University Hospital - Radiumhospitalet
  • Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)
  • Hospital Clinic Universitari de Barcelona
  • Institut Catala D'Oncologia
  • Hospital Universitario 12 De Octubre
  • Clinica Universidad de Navarra - Clinica Universitaria De Navarra
  • University Hospital of Geneva
  • Centre Hospitalier Universitaire Vaudois
  • Kantonsspital
  • UniversitaetsSpital
  • NHS Lothian - Western General Hospital
  • Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital
  • Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental Arm

Standard Arm

Arm Description

Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib

Radiotherapy + Temozolomide followed by adjuvant Temozolomide

Outcomes

Primary Outcome Measures

Overall Survival (OS)

Secondary Outcome Measures

Progression Free Survival (PFS)
Health-related Quality of life (HRQol)
HRQoL will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3.
Mini Mental State Examination (MMSE)

Full Information

First Posted
November 7, 2017
Last Updated
May 23, 2023
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Celgene, Canadian Cancer Trials Group
search

1. Study Identification

Unique Protocol Identification Number
NCT03345095
Brief Title
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
Acronym
MIRAGE
Official Title
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 26, 2018 (Actual)
Primary Completion Date
August 23, 2022 (Actual)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Celgene, Canadian Cancer Trials Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma. In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Newly Diagnosed Glioblastoma
Keywords
Marizomib, Temozolomide, Glioblastoma, Phase III

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
749 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental Arm
Arm Type
Experimental
Arm Description
Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
Arm Title
Standard Arm
Arm Type
Active Comparator
Arm Description
Radiotherapy + Temozolomide followed by adjuvant Temozolomide
Intervention Type
Drug
Intervention Name(s)
Marizomib
Other Intervention Name(s)
MRZ
Intervention Description
Intravenous administration of Marizomib
Intervention Type
Drug
Intervention Name(s)
Temozolomide
Other Intervention Name(s)
TMZ
Intervention Description
Oral Administration of Temozolomide
Intervention Type
Radiation
Intervention Name(s)
radiotherapy
Other Intervention Name(s)
RT
Intervention Description
60 Gy in 30 fractions over 6 weeks
Primary Outcome Measure Information:
Title
Overall Survival (OS)
Time Frame
From the date of randomization up to the date of death, assessed up to 49 months
Secondary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Time Frame
From the date of randomization until the date of first objective progression or the date of patient's death whichever occurs first, assessed up to 49 months
Title
Health-related Quality of life (HRQol)
Description
HRQoL will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3.
Time Frame
From randomization until progression, assessed up to 49 months
Title
Mini Mental State Examination (MMSE)
Time Frame
From the date of randomization until end of treatment, assessed up to 49 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed newly diagnosed glioblastoma (WHO grade IV) Tumor resection (gross total or partial), or biopsy only Availability of FFPE tumor block or 24 unstained slides for MGMT analysis Patient must be eligible for standard TMZ/RT + TMZ Karnofsky performance score (KPS) ≥ 70 Recovered from effects of surgery, postoperative infection and other complications of surgery (if any) The patient is at least 18 years of age on day of signing informed consent Stable or decreasing dose of steroids for at least 1 week prior to inclusion The patient has a life expectancy of at least 3 months Patient has undergone a brain MRI within 14 days of randomization but after intervention (resection or biopsy) The patient shows adequate organ functions as assessed by the specified laboratory values within 2 weeks prior to randomization defined as adequate bone marrow, renal and hepatic function within the following ranges: WBC ≥ 3×10*9/L ANC ≥ 1.5×10*9/L Platelet count of ≥ 100×10*9/L independent of transfusion Hemoglobin ≥ 10 g/dl Total Bilirubin ≤ 1.5 ULN ALT, AST, alkaline phosphatase (ALP) ≤ 2.5 × ULN Serum creatinine < 1.5 x ULN or creatinine clearance (CrCl) > 30 mL/min(using the Cockcroft-Gault formula) Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study treatment. Patients of childbearing / reproductive potential must agree to use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1 percent per year) when used consistently and correctly. Patients must also agree not to donate sperm during the study and for 6 months after receiving the last dose of study treatment. Women who are breast feeding must agree to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment. Ability to take oral medication Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Roth
Organizational Affiliation
EORTC Study Coordinator
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic Scottsdale
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Facility Name
University of California at Irvine
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
University of California
City
San Francisco
State/Province
California
ZIP/Postal Code
94143-0372
Country
United States
Facility Name
John Wayne Cancer Institute
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Facility Name
Mayo Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224-9980
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Ohio State University Comprehensive Cancer Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Penn State College of Medicine, Hershey Medical Center-Penn State Neuroscience Institute
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
Innsbruck Universitaetsklinik
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Kepler University Hospital
City
Linz
ZIP/Postal Code
4020
Country
Austria
Facility Name
Medical University Vienna - General Hospital AKH
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
Onze Lieve Vrouw Ziekenhuis
City
Aalst
ZIP/Postal Code
9300
Country
Belgium
Facility Name
GasthuisZusters Antwerpen - Sint-Augustinus
City
Antwerpen
Country
Belgium
Facility Name
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme
City
Bruxelles
ZIP/Postal Code
1070
Country
Belgium
Facility Name
Cliniques Universitaires Saint-Luc
City
Bruxelles
Country
Belgium
Facility Name
Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame
City
Charleroi
Country
Belgium
Facility Name
Universitair Ziekenhuis Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
C.H.U. Sart-Tilman
City
Liège
Country
Belgium
Facility Name
Saint John Regional Hospital
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
London Regional Cancer Center
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 4L6
Country
Canada
Facility Name
Ottawa Health Research Institute
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4K7
Country
Canada
Facility Name
Windsor Regional Cancer Centre
City
Windsor
State/Province
Ontario
Country
Canada
Facility Name
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Facility Name
BCCA - Abbotsford Centre
City
Abbotsford
Country
Canada
Facility Name
Tom Baker Cancer Centre
City
Calgary
ZIP/Postal Code
AB T2N 4N2
Country
Canada
Facility Name
QEII Health Sciences Centre-Capital District Health Authority
City
Halifax
ZIP/Postal Code
CA B3H 1V7
Country
Canada
Facility Name
Hamilton Health Sciences, Juravinski Cancer Centre
City
Hamilton
Country
Canada
Facility Name
Kingston Health Sciences Centre
City
Kingston
ZIP/Postal Code
CA K7L 2V7
Country
Canada
Facility Name
Montreal Neurological Institute and Hospital McGill University
City
Montréal
ZIP/Postal Code
H3A 2B4
Country
Canada
Facility Name
CHUM - Centre Hospitalier de l'Université de Montreal - Hopital Notre-Dame
City
Montréal
Country
Canada
Facility Name
Hopital Du Sacre-Coeur De Montreal
City
Montréal
Country
Canada
Facility Name
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
City
Québec
Country
Canada
Facility Name
Allan Blair Cancer Centre
City
Regina
Country
Canada
Facility Name
Sault Area Hospital
City
Sault Ste. Marie
Country
Canada
Facility Name
Regional Cancer Program of Hopital Reg. de Sudbury Reg. Hospital
City
Sudbury
Country
Canada
Facility Name
Odette Cancer Centre - Sunnybrook Health Sciences Centre
City
Toronto
Country
Canada
Facility Name
University Health Network - Oci / Princess Margaret Hospital
City
Toronto
Country
Canada
Facility Name
Centre hospitalier regional de Trois-Rivieres
City
Trois-Rivières
Country
Canada
Facility Name
BC Cancer Agency
City
Vancouver
ZIP/Postal Code
V5Z4E9
Country
Canada
Facility Name
Bcca - Vancouver Island Cancer Centre
City
Victoria
ZIP/Postal Code
BC V8R 6V5
Country
Canada
Facility Name
Cancercare Manitoba
City
Winnipeg
Country
Canada
Facility Name
Aarhus University Hospitals - Aarhus University Hospital (440)
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
Facility Name
University Hospitals Copenhagen - Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Centre Hospitalier Departemental Vendée
City
La Roche-sur-Yon
State/Province
Vendee
ZIP/Postal Code
85925
Country
France
Facility Name
CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer
City
Bron
ZIP/Postal Code
69677
Country
France
Facility Name
CHRU de Lille
City
Lille
Country
France
Facility Name
Institut de Cancerologie de l'Ouest
City
Nantes
Country
France
Facility Name
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
City
Paris
Country
France
Facility Name
Gustave Roussy
City
Villejuif
Country
France
Facility Name
Universitaetsklinikum Bonn
City
Bonn
ZIP/Postal Code
53105
Country
Germany
Facility Name
Universitaetsklinik Erlangen-Neurologische Klinik (3031)
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Klinikum Der J.W. Goethe Universitaet-Klinik und Poliklinik fur Neurochirurgie
City
Frankfurt
ZIP/Postal Code
60528
Country
Germany
Facility Name
UniversitaetsKlinikum Heidelberg - Head Hospital
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Universitaetsklinikum Leipzig-Klinik für Strahlentherapie und Radioonkologie
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
UniversitaetsMedizin Mannheim
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Technische Universitaet Muenchen - Klinikum Rechts Der Isar
City
Muenchen
ZIP/Postal Code
81675
Country
Germany
Facility Name
Universitaetskliniken Regensburg
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Universitaetsklinikum Tuebingen- Crona Kliniken
City
Tuebingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Catharina Ziekenhuis
City
Eindhoven
State/Province
North Brabant
ZIP/Postal Code
5602
Country
Netherlands
Facility Name
Spaarne Gasthuis - Vrije Universiteit Medisch Centrum
City
Amsterdam
Country
Netherlands
Facility Name
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
City
Amsterdam
Country
Netherlands
Facility Name
Medisch Centrum Haaglanden - Westeinde
City
Den Haag
ZIP/Postal Code
2501
Country
Netherlands
Facility Name
University Medical Center Groningen
City
Groningen
Country
Netherlands
Facility Name
Academisch Ziekenhuis Maastricht
City
Maastricht
ZIP/Postal Code
6202
Country
Netherlands
Facility Name
Radboud University Medical Center Nijmegen
City
Nijmegen
ZIP/Postal Code
6525
Country
Netherlands
Facility Name
Erasmus MC
City
Rotterdam
Country
Netherlands
Facility Name
Universitair Medisch Centrum - Academisch Ziekenhuis
City
Utrecht
ZIP/Postal Code
3584
Country
Netherlands
Facility Name
Oslo University Hospital - Radiumhospitalet
City
Oslo
Country
Norway
Facility Name
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)
City
Badalona
Country
Spain
Facility Name
Hospital Clinic Universitari de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Institut Catala D'Oncologia
City
L'Hospitalet De Llobregat
ZIP/Postal Code
08908
Country
Spain
Facility Name
Hospital Universitario 12 De Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Clinica Universidad de Navarra - Clinica Universitaria De Navarra
City
Pamplona
Country
Spain
Facility Name
University Hospital of Geneva
City
Geneva
Country
Switzerland
Facility Name
Centre Hospitalier Universitaire Vaudois
City
Lausanne
Country
Switzerland
Facility Name
Kantonsspital
City
Saint Gallen
Country
Switzerland
Facility Name
UniversitaetsSpital
City
Zürich
Country
Switzerland
Facility Name
NHS Lothian - Western General Hospital
City
Edinburgh
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Facility Name
Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital
City
London
Country
United Kingdom
Facility Name
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
City
Sheffield
ZIP/Postal Code
S10 2SJ
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

We'll reach out to this number within 24 hrs